![]() |
市场调查报告书
商品编码
1792369
神经血管内线圈市场报告(按产品类型(Guglielmi 可分离线圈、矩阵线圈)、适应症、应用、最终用户(医院、门诊手术中心、中风中心等)和地区)2025 年至 2033 年Neuroendovascular Coil Market Report by Product Type (Guglielmi Detachable Coils, Matrix Coils), Indication, Application, End User (Hospitals, Ambulatory Surgical Centers, Stroke Centers, and Others), and Region 2025-2033 |
2024 年全球神经血管内线圈市场规模达 10.252 亿美元。展望未来, IMARC Group预计到 2033 年市场规模将达到 12.839 亿美元,2025-2033 年期间的成长率 (CAGR) 为 2.66%。
神经血管内栓塞术是一种微创血管内治疗,用于阻断脑血管血流。动脉瘤是由血管壁薄弱引起的膨胀,可能因压力升高而破裂并导致出血进入脑部。动脉瘤破裂的症状通常包括突发性剧烈头痛、噁心、呕吐、视力模糊或复视、癫痫发作。在神经血管内栓塞术中,外科医生使用可拆卸的铂金弹簧圈紧紧地塞住动脉瘤,以促进血液凝固并降低外壁压力。神经血管内栓塞术因其成本低廉且患者风险低而在全球范围内越来越受欢迎。
神经血管内弹簧圈技术在形状、长度和生物活性方面取得了多项进展。此外,颅内支架在部署和传输方面也取得了显着进展。外科医生已开始将颅内支架与弹簧圈技术结合,以治疗动脉瘤并减少復发相关问题。此外,就术后併发症、良好疗效和復健而言,血管内弹簧圈被认为是一种比夹闭术更好的手术技术。除此之外,各种市场参与者都在投资引进技术先进的产品。例如,2018 年,强生医疗器材公司的子公司 Cerenovus 推出了 Galaxy G3 Mini 栓塞弹簧圈,该弹簧圈采用不规则形状设计,使其能够填充脑动脉瘤中的开放空间。
IMARC 集团的最新报告深入洞察了全球神经血管内线圈市场,涵盖了其所有重要方面。报告涵盖了从市场宏观概览到产业表现的微观细节、近期趋势、关键市场驱动因素和挑战、SWOT 分析、波特五力模型分析、价值链分析等。对于企业家、投资者、研究人员、顾问、商业策略家以及所有持有或计划以任何方式进入神经血管内线圈市场的人士而言,本报告都是必读之作。
The global neuroendovascular coil market size reached USD 1,025.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,283.9 Million by 2033, exhibiting a growth rate (CAGR) of 2.66% during 2025-2033.
Neuroendovascular coiling is a minimally invasive endovascular treatment which is performed to block the blood flow in a blood vessel in the brain. It is essential to treat an aneurysm, a bulge caused by weakness in the wall of a blood vessel, which can rupture due to rising pressure and bleed into the brain. The symptoms of a ruptured aneurysm generally include sudden onset of a severe headache, nausea, vomiting, blurred or double vision, and seizure. In neuroendovascular coiling, a surgeon tightly packs the aneurysm with detachable platinum coils that promote blood clotting and reduce pressure on the outer wall. Neuroendovascular coiling is becoming popular across the globe as it incurs less cost and lowers the risk for the patients.
Several advances have been made in the neuroendovascular coil technology in terms of shape, length and bioactivity. Besides this, significant progress has been made in intracranial stents to improve their deployment and delivery. Surgeons have started integrating intracranial stents with the coil technology to treat aneurysms and reduce issues related to recurrence. Moreover, endovascular coiling is being considered a better surgical technique than clipping regarding postoperative complications, favorable outcomes and rehabilitation. Other than this, various market players are investing in the introduction of technologically advanced products. For instance, in 2018, Cerenovus, a division of the Johnson & Johnson Medical Devices Companies, launched the Galaxy G3 Mini embolic coil which is designed to have an irregular shape to enable the device to fill open spaces in cerebral aneurysms.
IMARC Group's latest report provides a deep insight into the global neuroendovascular coil market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the neuroendovascular coil market in any manner.
The report has also analysed the competitive landscape of the market with some of the key players being Medtronic, Stryker Corporation, DePuy Synthes, Penumbra, Johnson & Johnson Services Inc., Terumo Corporation, Cardinal Health, Boston Scientific Corporation, Cook Medical Incorporated, Balt Extrusion, EndoShape, etc.